Pacira Pharmaceuticals Stock News

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TAMPA, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EXPAREL average daily sales at 105% of the prior year for the second quarter and 103% of the prior year for the month of June EXPAREL average daily sales at 105% of the prior year for the second quart

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Susan Mesco – Head-Investor Relations Dave Stack – Chairman and Chief Executive

Pacira (PCRX) delivered earnings and revenue surprises of -13.51% and 0.32%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Now is a good time to take a closer look at these stocks.

Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ClearBridge Small Cap Growth Strategy underperformed its index benchmark during Q1. Who were the leading detractors and contributors? Click here to find out.